Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa

被引:77
作者
Kang, CI
Kim, SH
Park, WB
Lee, KD
Kim, HB
Kim, EC
Oh, MD
Choe, KW
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Lab Med, Seoul, South Korea
[3] Seoul Natl Univ Hosp, Clin Res Inst, Seoul, South Korea
关键词
D O I
10.1089/mdr.2005.11.68
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study was conducted to evaluate risk factors for antimicrobial resistance and influence of resistance on mortality in Pseudomonas aeruginosa bacteremia. Data on 190 patients with P. aeruginosa bacteremia were analyzed retrospectively. Antimicrobial resistance to antipseudomonal antibiotics was evaluated. The main outcome measure was 30-day mortality. In P. aeruginosa bacteremia, resistance rates to piperacillin (PIP), ceftazidime (CAZ), ciprofloxacin (CIP), and imipenem (IPM) were 29 (56/190), 19 (36/190), 17 (32/190) and 15% (28/190), respectively. Prior uses of fluoroquinolones or carbapenems were independent risk factors for resistance to CIP and IPM, and prior use of extended-spectrum cephalosporins was a risk factor for PIP-R. An indwelling urinary catheter was a risk factor for PIP-R, CAZ-R, and CIP-R. An invasive procedure was a risk factor for CIP-R and IPM-R. The 30-day mortality rate was 44% (33/75) in patients infected by strains resistant to any of the antipseudomonal antibiotics, but 33.9% (39/115) in those by strains susceptible to all antipseudomonal antibiotics (p = 0.161). Among patients with bloodstream infection due to antimicrobial-resistant P. aeruginosa, those infected by IPM-R strains had the highest mortality (IPM-R, 53.6% vs. CAZ-R, 47.2% vs. CIP-R 46.9%, PIP-R, 39.3%). In this study regarding P. aeruginosa bacteremia, prior uses of fluoroquinolones, carbapenems, or extended-spectrum cephalosporins, a prior invasive procedure, and an indwelling urinary catheter were found to be associated with antimicrobial resistance. The patients with bloodstream infection caused by antimicrobial-resistant P. aeruginosa, especially to imipenem, had a tendency toward higher mortality than those infected by susceptible strains.
引用
收藏
页码:68 / 74
页数:7
相关论文
共 24 条
  • [11] Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa
    Hyatt, JM
    Schentag, JJ
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2000, 21 (01) : S9 - S11
  • [12] Jorgensen J., 1999, MANUAL CLIN MICROBIO
  • [13] Pseudomonas aeruginosa bacteremia:: Risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome
    Kang, CI
    Kim, SH
    Kim, HB
    Park, SW
    Choe, YJ
    Oh, MD
    Kim, EC
    Choe, KW
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (06) : 745 - 751
  • [14] Khayr W, 2000, Am J Ther, V7, P309, DOI 10.1097/00045391-200007050-00007
  • [15] APACHE-II - A SEVERITY OF DISEASE CLASSIFICATION-SYSTEM
    KNAUS, WA
    DRAPER, EA
    WAGNER, DP
    ZIMMERMAN, JE
    [J]. CRITICAL CARE MEDICINE, 1985, 13 (10) : 818 - 829
  • [16] Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections
    Lautcnbach, E
    Fishman, NO
    Bilker, WB
    Castiglioni, A
    Metlay, JP
    Edelstein, PH
    Strom, BL
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (21) : 2469 - 2477
  • [17] Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae:: Risk factors for infection and impact of resistance on outcomes
    Lautenbach, E
    Patel, JB
    Bilker, WB
    Edelstein, PH
    Fishman, NO
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 32 (08) : 1162 - 1171
  • [18] Nosocomial infections with ceftazidime-resistant Pseudomonas aeruginosa:: Risk factors and outcome
    Lee, SC
    Fung, CP
    Ziu, PYF
    Wang, TC
    See, LC
    Lee, N
    Chen, SC
    Shieh, WB
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 1999, 20 (03) : 205 - 207
  • [19] National Committee on Clinical Laboratory Standards, 2000, M2A7 NAT COMM CLIN L, V7
  • [20] SCHIMPFF SC, 1974, J INFECT DIS S, V130, P24